Rodman & Renshaw Initiates Coverage On Trevi Therapeutics with Buy Rating, Announces Price Target of $7
Portfolio Pulse from Benzinga Newsdesk
Rodman & Renshaw has initiated coverage on Trevi Therapeutics with a Buy rating and set a price target of $7.
June 13, 2024 | 5:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rodman & Renshaw has initiated coverage on Trevi Therapeutics with a Buy rating and set a price target of $7.
The initiation of coverage with a Buy rating and a specific price target of $7 by Rodman & Renshaw is likely to positively influence investor sentiment and could lead to a short-term increase in TRVI's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100